Orthofix Medical Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter earnings filing. Orthofix is a global spine and orthopedics medical-device company; Global Spine generated 77% of sales and Global Orthopedics 23%.
Financial performance
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net sales | $464.5 million | $406.6 million |
| Gross profit / margin | $349.6 million / 75.3% | $304.7 million / 74.9% |
| Operating loss | $8.3 million | $6.3 million |
| Loss before income taxes | $13.5 million | $0.4 million |
| Income tax expense (benefit) | $24.9 million expense | $2.9 million benefit |
| Net income (loss) | $(38.4) million | $2.5 million |
| Net cash from operating activities | $18.5 million | $74.3 million |
| Free cash flow | $(1.1) million | $57.2 million |
- Sales grew 14.2% reported and 13.5% at constant currency. Both segments recorded growth: Global Spine rose 11.6% to $359.0 million; Global Orthopedics rose 24.4% to $105.5 million.
- Within Global Spine, Spinal Implants grew 21.3% to $115.1 million, Bone Growth Therapies grew 9.4% to $187.4 million, and Biologics grew 1.7% to $56.4 million. Global Orthopedics growth included FITBONE momentum and a favorable $2.6 million currency effect.
- Gross margin increased 0.4 percentage points year over year, reflecting recovery in volumes and fixed-cost absorption and fewer prior-year inventory charges; unfavorable product mix and higher semiconductor procurement costs partly offset the improvement.
- Management’s segment measure, EBITDA, was $29.7 million versus $32.7 million. Global Spine EBITDA was $58.0 million, Global Orthopedics $3.4 million, and Corporate $(31.7) million.
Liquidity, debt and capital resources
- Cash and cash equivalents were $87.8 million at year-end, down from $96.3 million; operating cash flow fell $55.8 million year over year. The filing attributes the decline primarily to lower earnings and working-capital movements, including the CMS advance-payment liability and receivables.
- Capital expenditures were $19.6 million, producing negative free cash flow of $1.1 million. Inventory was $83.0 million; receivables were $78.6 million. Days sales outstanding were 58 days, versus 57, and inventory turns improved to 1.4 from 1.2.
- No borrowings were outstanding on the $300 million secured revolving credit facility at year-end; it matures October 25, 2024. The company also reported no borrowings on its €5.5 million Italian line. Finance-lease liabilities totaled $22.5 million; the filing reports no outstanding funded revolver debt.
- The revolver includes leverage and interest-coverage covenants. The company reported compliance at year-end. The remaining $4.8 million CMS Accelerated and Advance Payment Program balance was classified as a current liability and is recouped from Medicare payments.
Material changes and unusual items
- Net sales exceeded FY2019’s $460.0 million after the COVID-related decline in FY2020, but net income and operating cash flow weakened from FY2020.
- A full $11.8 million impairment of Global Orthopedics goodwill was recorded in the fourth quarter, citing the reporting unit’s fair value being below carrying value. No Global Spine goodwill impairment was identified.
- The company recorded $24.9 million of income tax expense despite a $13.5 million pretax loss. It cited a $26.2 million net increase in deferred-tax valuation allowances, including a full valuation allowance against the U.S. net deferred tax asset, and prior-year tax benefits that did not recur.
- Spinal Kinetics contingent consideration was valued at $17.2 million at year-end. A $15.0 million sales milestone was paid in 2021; a further $30.0 million payment may be due if the remaining revenue milestone is achieved. Management expected achievement within the next 12 months.
- Orthofix invested in and loaned funds to Neo Medical; the related convertible loans and preferred shares had reported fair values of $7.1 million and $5.4 million, respectively. The filing cautions that the investment may not be recoverable.
- A technology assignment and royalty agreement with a company partially owned and controlled by the CEO’s wife provided for up to $10.0 million in consideration, including contingent payments and sales royalties. The filing says the Audit and Finance Committee supervised negotiations and the CEO was excluded from them and related oversight.
- An Italian Medical Device Payback liability of $5.2 million remained accrued; the law’s implementation was uncertain. Temporary relief resulted in a $1.2 million benefit in FY2021.
Outlook, commentary and principal risks
- The filing provides no specific numerical FY2022 revenue or earnings guidance. Management said the pandemic’s future impact remained uncertain, with elective procedure volumes exposed to new COVID-19 waves, hospital capacity constraints and staffing shortages.
- Management cited recovery in procedure volumes and continued adoption of the M6-C artificial cervical disc as growth drivers. The company is pursuing new products, clinical studies and market expansion, while increasing research and development expense to $49.6 million from $39.1 million.
- Risks include elective-surgery disruption, supply-chain constraints (including semiconductor shortages), labor availability, dependence on distributors and third-party manufacturers, reimbursement and pricing pressure, regulatory approvals and EU Medical Device Regulation compliance costs through 2024.
- Additional risks include dependence on MTF Biologics for allograft supply and marketing fees, competition, product liability and litigation, foreign-exchange exposure, cybersecurity, and uncertain tax and regulatory outcomes. The company reported a $4.0 million foreign-currency transaction loss in 2021.
Investor verification checklist
- Assess whether sales growth and segment performance are supported by sustained procedure-volume recovery, particularly given the pandemic and hospital staffing risks.
- Review the drivers of the $38.4 million net loss, especially the goodwill impairment, deferred-tax valuation allowances and other non-recurring items.
- Track operating cash flow, working capital and repayment of the remaining CMS advance, alongside capital spending and free cash flow.
- Verify the timing and potential cash cost of the remaining $30.0 million Spinal Kinetics milestone and the assumptions underlying its $17.2 million fair value.
- Evaluate the recoverability and valuation assumptions for Neo Medical investments, the related-party technology agreement, and the $5.2 million Italian payback accrual.
- Confirm ongoing covenant compliance and the company’s liquidity position; distinguish funded debt from its finance-lease obligations.